MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	4/14/2005 10:06:21 AM
	Read Replies (1) of 1826

MGI Pharma "outperform," estimates reduced Thursday, April 14, 2005 3:14:40 AM ET Robert W. Baird NEW YORK, April 14 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on MGI Pharma (MOGN.NAS), while reducing their estimates for the company. The target price is set to $35. In a research note published this morning, the analysts mention that the company reported its 1Q05 non-GAAP EPS marginally short of the estimates due to lower-than-expected revenues. MGI Pharma's revenues from the Aloxi drug were short of the estimates on account of the short-term sluggishness in oncology practice in January, the analysts say. The company has reiterated its Aloxi guidance for FY05 due to a possible strengthening in the sales trends, Robert W Baird adds. The EPS estimates for 2005 and 2006 have been reduced from $0.56 to $0.54 and from $1.11 to $1.07, respectively.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next